MIRO Key Statistics, Chart & Performance
The current stock price of MIRO is 3.39 USD. In the past month the price increased by 1.5%. In the past year, price increased by 17.71%.
MIRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.55 | 231.87B | ||
| DHR | DANAHER CORP | 30.55 | 166.39B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 196.3 | 59.65B | ||
| A | AGILENT TECHNOLOGIES INC | 26.49 | 41.90B | ||
| IQV | IQVIA HOLDINGS INC | 21.01 | 41.60B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.15 | 30.05B | ||
| WAT | WATERS CORP | 31.45 | 23.78B | ||
| ILMN | ILLUMINA INC | 34.44 | 22.94B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.38 | 20.03B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.87 | 17.27B | ||
| TEM | TEMPUS AI INC | N/A | 12.41B | ||
| RVTY | REVVITY INC | 21.5 | 11.68B |
Related stock screener links
About MIRO
Company Profile
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
Company Info
MIROMATRIX MEDICAL INC
6455 Flying Cloud Drive, Suite 107
Eden Prairie MINNESOTA US
CEO: Jeff Ross
Employees: 76
Phone: 16122027026
MIROMATRIX MEDICAL INC / MIRO FAQ
What does MIROMATRIX MEDICAL INC do?
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
What is the stock price of MIROMATRIX MEDICAL INC today?
The current stock price of MIRO is 3.39 USD. The price increased by 0.59% in the last trading session.
Does MIROMATRIX MEDICAL INC pay dividends?
MIRO does not pay a dividend.
How is the ChartMill rating for MIROMATRIX MEDICAL INC?
MIRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about MIROMATRIX MEDICAL INC (MIRO) stock?
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.
What is the Price/Earnings (PE) ratio of MIROMATRIX MEDICAL INC (MIRO)?
MIROMATRIX MEDICAL INC (MIRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
Would investing in MIROMATRIX MEDICAL INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MIRO.
MIRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MIRO. When comparing the yearly performance of all stocks, MIRO is one of the better performing stocks in the market, outperforming 96.98% of all stocks.
MIRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MIRO. While MIRO seems to be doing ok healthwise, there are quite some concerns on its profitability.
MIRO Financial Highlights
Over the last trailing twelve months MIRO reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 17.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| Debt/Equity | 0.03 |
MIRO Forecast & Estimates
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.
For the next year, analysts expect an EPS growth of 32.47% and a revenue growth -6.67% for MIRO